Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study of TSR-022 Monotherapy or in Combination with TSR-042 in Patients with Colorectal Cancer and Post-PD-1 Non-Small Cell Lung Cancer and Melanoma

Trial Profile

A Phase 1, Open-Label Study of TSR-022 Monotherapy or in Combination with TSR-042 in Patients with Colorectal Cancer and Post-PD-1 Non-Small Cell Lung Cancer and Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Cobolimab (Primary) ; Dostarlimab (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms AMBER
  • Most Recent Events

    • 09 Nov 2018 According to a TESARO media release, the monotherapy and combination dose-escalation parts of the study are complete.
    • 09 Nov 2018 According to a TESARO media release, additional data from this study are expected in 2019.
    • 09 Nov 2018 According to a TESARO media release, initial data from this study were presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Conference in Washington, D.C.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top